Peptide Schedule
Carbetocin (Duratocin/Pabal)9 residues (approx.)CYITNCPLGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Carbetocin (Duratocin/Pabal) Dosage Calculator
Carbetocin is an octapeptide synthetic analog of oxytocin with a longer duration of action, designed specifically for the prevention of uterine atony and postpartum hemorrhage (PPH).
100mcg · Single dose
Summary: Add 0mL BAC water to your 0.1mg vial. Draw to < 0.1 units on a U-100 syringe for a 100mcg dose. This vial will last 0 doses.
Cycle Planner
Carbetocin (Duratocin/Pabal) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = 33-55 minutes (IV: ~33 min, IM: ~55 min)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Carbetocin (Duratocin/Pabal) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Single dose |
| Moderate | 100mcg | Single dose |
| Aggressive | 100mcg | Single dose |
Note: Carbetocin (trade names Duratocin, Pabal) is a long-acting synthetic oxytocin analog approved in the EU, Canada, Australia, and many other countries for the prevention of postpartum hemorrhage following cesarean section or vaginal delivery. It is NOT FDA-approved in the United States. A heat-stable formulation was added to the WHO Model List of Essential Medicines in 2019 following the landmark CHAMPION trial, making it particularly important for low-resource settings where cold-chain storage of oxytocin is unreliable. Carbetocin is administered as a single 100 mcg dose — no repeat dosing is required due to its prolonged duration of action (~60 minutes of uterotonic activity). It is intended exclusively for postpartum use and must only be administered after delivery of the infant.
About Carbetocin (Duratocin/Pabal)
Carbetocin is an octapeptide synthetic analog of oxytocin with a longer duration of action, designed specifically for the prevention of uterine atony and postpartum hemorrhage (PPH). Structurally, it differs from native oxytocin through a deamination of the cysteine residue at position 1 and replacement of the disulfide bridge with a thioether linkage, rendering it resistant to enzymatic degradation by aminopeptidases and disulfidases. This modification extends its biological half-life approximately 4-10 fold compared to oxytocin while preserving full agonist activity at myometrial oxytocin receptors. At the molecular level, carbetocin is a functionally selective Gq agonist at the oxytocin receptor (OXTR), selectively activating the Gq/phospholipase C signaling cascade that drives myometrial contraction without significant activity at vasopressin V1a or V1b receptors. Uniquely, carbetocin induces beta-arrestin-independent internalization of the OXTR, and once internalized, the receptor does not recycle back to the plasma membrane — a feature that may contribute to its sustained uterotonic effect. The uterotonic response begins within 2 minutes of intravenous administration, with sustained rhythmic contractions observable for approximately 60 minutes, compared to only 10-15 minutes with equimolar oxytocin. The WHO-led CHAMPION trial (2018), the largest clinical trial ever conducted on PPH prevention, enrolled nearly 30,000 women across 23 sites in 10 countries and demonstrated that heat-stable carbetocin (100 mcg IM) was non-inferior to oxytocin (10 IU IM) for preventing blood loss of 500 mL or greater after vaginal birth. This pivotal trial led WHO to update its PPH prevention guidelines in 2018 and add heat-stable carbetocin to the Model List of Essential Medicines in 2019. Carbetocin offers logistical advantages over oxytocin in resource-limited settings because its heat-stable formulation does not require cold-chain storage, maintaining efficacy at temperatures up to 30 degrees Celsius for 3 years. Multiple randomized controlled trials in cesarean delivery settings have shown carbetocin reduces the need for additional uterotonic agents by 30-50% compared to standard oxytocin protocols. Carbetocin is currently approved in over 40 countries including EU member states (as Pabal), Canada (as Duratocin), Australia, Singapore, and multiple countries in Latin America, Asia, and Africa. It has not received FDA approval in the United States and remains classified as a research compound in the US market.